Physician profile
Roman Krol
NPI 1477500569
$4,193.63
in general payments reported to CMS, 2019-2025
31 companies · $1,871 in 2025
The $1,871 reported for 2025 was more than what 86% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $114 · 2021: $54.60 · 2022: $217 · 2023: $508 · 2024: $1,286 · 2025: $1,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,558 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,558.34 |
| Education | $107.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,579.30 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $431.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $414.23 | 2020-2025 | Tezspire, Airsupra, Fasenra |
| Harmony Biosciences LLC | $247.57 | 2023-2025 | Wakix |
| Amgen INC. | $175.01 | 2023-2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $144.55 | 2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $138.77 | 2021-2025 | Dupixent |
| Genzyme Corporation | $119.92 | 2022-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $103.91 | 2024 | Lumryz |
| Verona Pharma, INC. | $93.38 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $79.39 | 2024-2025 | Prolastin-C Liquid |
| Insmed, INC. | $74.22 | 2024-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.93 | 2024 | Ofev |
| Axsome Therapeutics, INC. | $66.95 | 2024-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $62.91 | 2024-2025 | Uptravi, Opsumit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $59.62 | 2024-2025 | Inspire |
| Genentech USA, INC. | $47.50 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $40.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.51 | 2025 | Aralast |
| Mylan Specialty L.P. | $33.04 | 2024 | Yupelri |
| Resmed Corp | $19.13 | 2024 | |
| Lilly USA, LLC | $18.37 | 2025 | Zepbound |
| United Therapeutics Corporation | $18.34 | 2025 | Tyvaso |
| 3b Medical, INC. | $18.25 | 2024 | Luna |
| Philips North America LLC | $17.57 | 2025 | Vest Therapy Und |
| Nabriva Therapeutics, Plc | $17.11 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.72 | 2024 | Eliquis |
| Breas Medical, INC. | $14.61 | 2024 | Vivo 45 Ls |
| Merck Sharp & Dohme LLC | $13.22 | 2023 | |
| Veran Medical Technologies, INC. | $7.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Krol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.